Dr. Mauro Ferrari was appointed to the Arrowhead Board of Directors in 2010. Dr. Ferrari currently serves as Professor of Pharmaceutics at the University of Washington in Seattle, WA and CEO of DXT Pharmaceutics in Menlo Park, CA.
In the decade 2010-2019, he was President and CEO of The Houston Methodist Hospital Research Institute (TMHRI), where he also served as Executive Vice President of Houston Methodist Hospital, and Senior Associate Dean of Weill Cornell Medical College in New York. He also served as President of the European Research Council. Dr. Ferrari is an internationally recognized expert in nanomedicine and biomedical nanotechnology. Prior to assuming leadership of TMHRI, Dr. Ferrari was Professor and Chairman of The Department of NanoMedicine and Biomedical Engineering at The University of Texas Health Science Center at Houston, Professor of Experimental Therapeutics at the MD Anderson Cancer Center, Adjunct Professor of Bioengineering at Rice University, and Adjunct Professor of Biomedical Engineering at the University of Texas in Austin. His previous academic appointments include tenured professorships at his graduate Alma Mater UC Berkeley, and The Ohio State University.
From 2003 to 2005, Dr. Ferrari served as Special Expert on Nanotechnology and Eminent Scholar at The National Cancer Institute, where he led in the development of NCI’s program in Nanotechnology, which remains the largest program in NanoMedicine in the world. Dr. Ferrari has been serving as the Editor-in-Chief for “Biomedical Microdevices: BioMEMS and Biomedical Nanotechnology” since 1997. We believe Dr. Ferrari’s qualifications to serve on the Board include his extensive training and experience in the fields of nanotechnology, biotechnology and biomedical applications. Dr. Ferrari has significant technical training in mathematics, engineering, medicine, and business, about 500 published articles, over 50 issued patents, and is the recipient of most prestigious academic awards in nanomedicine, the pharmaceutical sciences, and drug delivery technology. Additionally, Dr. Ferrari has extensive experience in developmental stage organizations having founded several startup companies.
What is Mauro Ferrari's net worth?
The estimated net worth of Mauro Ferrari is at least $602,385.95 as of October 9th, 2020. Dr. Ferrari owns 30,971 shares of Arrowhead Pharmaceuticals stock worth more than $602,386 as of December 21st. This net worth estimate does not reflect any other assets that Dr. Ferrari may own. Learn More about Mauro Ferrari's net worth.
How do I contact Mauro Ferrari?
Has Mauro Ferrari been buying or selling shares of Arrowhead Pharmaceuticals?
Mauro Ferrari has not been actively trading shares of Arrowhead Pharmaceuticals during the past quarter. Most recently, Mauro Ferrari sold 10,000 shares of the business's stock in a transaction on Friday, October 9th. The shares were sold at an average price of $48.00, for a transaction totalling $480,000.00. Following the completion of the sale, the director now directly owns 30,971 shares of the company's stock, valued at $1,486,608. Learn More on Mauro Ferrari's trading history.
Who are Arrowhead Pharmaceuticals' active insiders?
Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Javier San Martin (Insider), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Arrowhead Pharmaceuticals?
In the last year, Arrowhead Pharmaceuticals insiders bought shares 2 times. They purchased a total of 2,000 shares worth more than $54,990.00. In the last year, insiders at the biotechnology company sold shares 14 times. They sold a total of 246,092 shares worth more than $7,898,458.13. The most recent insider tranaction occured on December, 18th when CEO Christopher Richard Anzalone sold 26,712 shares worth more than $567,362.88. Insiders at Arrowhead Pharmaceuticals own 4.5% of the company.
Learn More about insider trades at Arrowhead Pharmaceuticals. Information on this page was last updated on 12/18/2024.
